Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Shares of weight-loss drugmakers Novo Nordisk and Eli Lilly rose on Tuesday after U.S. President Joe Biden proposed expanding ...

With expected sales for GLP1Rs in obesity estimated to surpass $126 billion by 2030, this drug category presents a lucrative ...

The stocks of companies that make the new class of drugs to treat obesity and manage diabetes were higher across the board ...

The White House said it's moving to make the federal health insurance plans pay for anti-obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound for people who are obese, even if they don ...

Shares of Eli Lilly LLY and Novo Nordisk NVO were up on Tuesday, likely due to a proposal by President Biden that Medicare ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

Share on Facebook Share on Twitter Under a new rule the Biden administration proposed on Tuesday, millions of Americans with ...

The Biden administration plans to require Medicare and Medicaid to offer coverage of weight loss medications for people seeking obesity treatment.The new rule, which was proposed by the administration ...

The Biden administration proposed a rule to let Medicare and Medicaid cover obesity drugs like Ozempic. Millions would ...